Business Update4 May 2026, 08:27 am
OneSource Supports 2nd Generic Semaglutide Approval in Canada
AI Summary
OneSource Specialty Pharma Ltd's partner, Orbicular, along with its Canadian front-end partner, received approval from Health Canada for a generic version of Ozempic® (semaglutide injection). This marks the second generic semaglutide approval in Canada, positioning OneSource partners as the first generic entrants in one of the world’s most significant semaglutide markets. OneSource supported the program as the manufacturing partner, providing end-to-end manufacturing capabilities for the Canadian filing. Commercial supply will be supported from OneSource’s US FDA-approved flagship facility in Bengaluru.
Key Highlights
- OneSource's partner receives approval for generic semaglutide in Canada.
- This is the second generic semaglutide approval in Canada.
- OneSource provided manufacturing support for the Canadian filing.
- Commercial supply will be supported from OneSource’s US FDA-approved facility.
- Approval reinforces OneSource's presence in complex peptide-based programs.